Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma


( Last Updated : January 15, 2019)
Project Line:
Health Technology Review
Project Sub Line:
Optimal Use
Project Number:
OP0538-000 / CT0001

Details


Final Biosimilar Summary Dossier Issued:

Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and children and young adults with relapsed or refractory acute lymphoblastic leukemia.

CADTH undertook a review of manufacturer-submitted materials and published literature to assess the clinical impact, cost-effectiveness, and implementation considerations, including patient and caregiver perspectives and experiences, ethical considerations, and other considerations, such as facilities for the administration of CAR T-cell therapy, therapy eligibility, travel requirements, and resource costs associated with the provision of tisagenlecleucel therapy in Canada.

The project has following key components:

  • protocols
  • clinical systematic review
  • economic review
  • review of implementation considerations, ethics, and patient and caregiver perspectives and experiences
  • recommendations report.

Read more about CAR T-cell therapy reviews at CADTH.


Files

Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma

Optimal Use

In Brief

PUBLISHED: January 15, 2019

 

Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations

Optimal Use

Recommendation Report

PUBLISHED: January 15, 2019

 

Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report

Optimal Use

Clinical Report

PUBLISHED: January 15, 2019

 

Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Ethics and Implementation Report

Optimal Use

Ethics and Implementation Report

PUBLISHED: January 15, 2019

 

Tisagenlecleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report

Optimal Use

Economic Review Report - DLBCL

PUBLISHED: January 15, 2019

 

Tisagenlecleucel for Acute Lymphoblastic Leukemia: Economic Review Report

Optimal Use

Economic Review Report - ALL

PUBLISHED: January 15, 2019

 

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Clinical Section

Optimal Use

Project Protocol, Clinical Section
Volume 8, Issue 3a

PUBLISHED: September 6, 2018

 

Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma — Project Protocol, Implementation and Ethics Section

Optimal Use

Project Protocol, Implementation and Ethics Section
Volume 8, Issue 3b

PUBLISHED: September 21, 2018

 

Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma -Patient Input Submissions

Optimal Use

Patient Input Submissions

PUBLISHED: December 11, 2018

Files